Sales & Marketing One year later, EVERSANA plans to go beyond the AI agency At an event in New York City, EVERSANA shared updates, customer perspectives, and future plans for its AI agency, which is moving beyond that mandate.
News Apnimed IPO raises $192m, as three other biotechs set terms Sleep apnoea drug developer Apnimed has completed its IPO, raising $192m, while Braveheart, Attovia, and Vogenx reveal their terms.
News Scribe raises $155m in IPO, as Apnimed pitches for $150m Gene-editing specialist Scribe becomes the 14th biotech to list on the Nasdaq this year, as sleep apnoea drug developer Apnimed prices its listing.
News Sleep apnoea drug firm Apnimed files for IPO Apnimed has joined the IPO queue on the Nasdaq, hoping to raise additional funding for its late-stage oral therapy for obstructive sleep apnoea.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.